TSMHT
BEAM icon

Thurston Springer Miller Herd & Titak’s Beam Therapeutics BEAM Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-97
Closed -$1.65K – 609
2025
Q2 		$1.65K Hold
97
– – ﹤0.01% 1445
2025
Q1 		$1.89K Hold
97
– – ﹤0.01% 1448
2024
Q4 		$2.4K Hold
97
– – ﹤0.01% 1111
2024
Q3 		$2.38K Hold
97
– – ﹤0.01% 1307
2024
Q2 		$2.27K Buy
+97
New +$2.38K ﹤0.01% 1290

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's BEAM Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Beam Therapeutics (BEAM) in Q3 2025, closing a stake of 97 shares — an estimated $1.65K sold.

Thurston Springer Miller Herd & Titak first reported a position in BEAM in Q2 2024 and held it in 5 quarters. The position peaked at $2.4K in Q4 2024. 219 funds tracked by Wall St. Rank hold BEAM as of Q3 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining Beam Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 97 Beam Therapeutics shares in Q3 2025, an estimated $1.65K.
  • Thurston Springer Miller Herd & Titak first reported a position in Beam Therapeutics in Q2 2024 and held it in 5 quarters.
  • Thurston Springer Miller Herd & Titak's Beam Therapeutics position peaked at $2.4K in Q4 2024.
  • 219 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.